Cargando…
EGFR基因突变状态未知NSCLC治疗——TKI还是化疗？
At present, the treatment recommendations of advanced non-small cell lung cancer (NSCLC) with clear epidermal growth factor receptor (EGFR) gene status has reached a consensus: patients with EGFR mutation-positive NSCLC can give priority to epidermal growth factor receptor-tyrosine kinase inhibitors...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000400/ https://www.ncbi.nlm.nih.gov/pubmed/25342036 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.10.01 |